Holen Sie sich die Stockscreener-App
4.25
0.71%
0.03
Handel nachbörslich:
4.25
Schlusskurs vom Vortag:
$4.22
Offen:
$4.29
24-Stunden-Volumen:
323.61K
Relative Volume:
0.38
Marktkapitalisierung:
$156.91M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-144.01M
KGV:
-1.0599
EPS:
-4.01
Netto-Cashflow:
$-113.02M
1W Leistung:
-5.13%
1M Leistung:
+9.54%
6M Leistung:
-20.11%
1J Leistung:
-76.04%
1-Tages-Spanne:
$4.22
$4.43
1-Wochen-Bereich:
$4.13
$4.59
52-Wochen-Spanne:
$3.61
$20.21
Biomea Fusion Inc Stock (BMEA) Company Profile
Firmenname
Biomea Fusion Inc
Sektor
Branche
Telefon
(650) 980-9099
Adresse
900 MIDDLEFIELD ROAD, REDWOOD CITY
Vergleichen Sie BMEA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BMEA
Biomea Fusion Inc
|
4.25 | 156.91M | 0 | -144.01M | -113.02M | -4.01 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.40 | 113.67B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
683.08 | 74.97B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
665.68 | 40.50B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
277.16 | 35.95B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
120.88 | 29.63B | 3.30B | -501.07M | 1.03B | -2.1146 |
Biomea Fusion Inc Stock (BMEA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-10-09 | Eingeleitet | Edward Jones | Buy |
| 2024-09-27 | Hochstufung | Rodman & Renshaw | Neutral → Buy |
| 2024-09-27 | Hochstufung | Truist | Hold → Buy |
| 2024-08-29 | Eingeleitet | CapitalOne | Overweight |
| 2024-06-11 | Herabstufung | Truist | Buy → Hold |
| 2024-06-07 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2024-04-02 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-02-06 | Eingeleitet | Truist | Buy |
| 2023-07-27 | Eingeleitet | Scotiabank | Sector Outperform |
| 2023-06-26 | Herabstufung | Jefferies | Buy → Hold |
| 2023-05-12 | Eingeleitet | Barclays | Overweight |
| 2023-03-29 | Bestätigt | Oppenheimer | Outperform |
| 2023-03-28 | Bestätigt | H.C. Wainwright | Buy |
| 2023-02-24 | Eingeleitet | Citigroup | Buy |
| 2022-06-02 | Fortgesetzt | H.C. Wainwright | Buy |
| 2022-01-12 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-12-17 | Eingeleitet | Oppenheimer | Outperform |
| 2021-05-11 | Eingeleitet | JP Morgan | Overweight |
| 2021-05-11 | Eingeleitet | Jefferies | Buy |
| 2021-05-11 | Eingeleitet | Piper Sandler | Overweight |
Alle ansehen
Biomea Fusion Inc Aktie (BMEA) Neueste Nachrichten
Barclays PLC Purchases 24,162 Shares of Biomea Fusion, Inc. (NASDAQ:BMEA) - Defense World
HC Wainwright Reaffirms Buy Rating for Biomea Fusion (NASDAQ:BMEA) - MarketBeat
Biomea Fusion to Become a Diabetes & Obesity Medicines Company - GlobeNewswire
Biomea Fusion Pivots to Diabetes Focus After Breakthrough Drug Shows 1.5% HbA1c Reduction - StockTitan
Biomea Fusion (NASDAQ:BMEA) Earns “Buy” Rating from D. Boral Capital - Defense World
Biomea Fusion, Inc. (NASDAQ:BMEA) Receives Average Rating of “Buy” from Analysts - Defense World
Biomea Fusion, Inc. (NASDAQ:BMEA) Given Average Rating of "Buy" by Analysts - MarketBeat
Biomea Fusion's (BMEA) Buy Rating Reaffirmed at D. Boral Capital - MarketBeat
Recent uptick might appease Biomea Fusion, Inc. (NASDAQ:BMEA) institutional owners after losing 75% over the past year - Simply Wall St
BMEABiomea Fusion, Inc. Latest Stock News & Market Updates - StockTitan
Biomea Fusion Reports New Preclinical Data on Icovamenib-Semaglutide Combination Study - GlobeNewswire
Biomea's Icovamenib Boosts Semaglutide Effects: 11.5% Extra Weight Loss, 43% More Muscle Mass - StockTitan
10 Best Diabetes Stocks To Buy Under $10 - Insider Monkey
Here’s Why Biomea Fusion, Inc. (NASDAQ:BMEA) Is Among the Best Diabetes Stocks to Buy Under $10 - Insider Monkey
Biomea Fusion to Present at the 43rd Annual J.P. Morgan Healthcare Conference - GlobeNewswire
Biomea Fusion CEO to Present at J.P. Morgan Healthcare Conference 2025 - StockTitan
Geode Capital Management LLC Raises Holdings in Biomea Fusion, Inc. (NASDAQ:BMEA) - Defense World
Barclays PLC Increases Stock Position in Biomea Fusion, Inc. (NASDAQ:BMEA) - Defense World
Biomea Fusion, Inc. (NASDAQ:BMEA) Short Interest Update - Defense World
State Street Corp Decreases Stock Position in Biomea Fusion, Inc. (NASDAQ:BMEA) - Defense World
Biomea Fusion (BMEA) – Analysts’ Weekly Ratings Changes - Defense World
Biomea Fusion Advances Diabetes Treatment with Positive Study Results - TipRanks
Biomea Fusion's SWOT analysis: clinical hold casts shadow on diabetes drug stock - Investing.com
Biomea Fusion shares hold with Buy rating after trial success By Investing.com - Investing.com Australia
Biomea Fusion shares hold with Buy rating after trial success - Investing.com
Biomea stock sinks 16% after Phase 2 data release - MSN
Biomea Fusion's (BMEA) Buy Rating Reiterated at D. Boral Capital - MarketBeat
Biomea Fusion Announces Positive Topline Results from Ongoing Phase II COVALENT-111 Study in Patients with Type 2 Diabetes - The Manila Times
Biomea Fusion Announces Positive Topline Results from - GlobeNewswire
Biomea Fusion's Diabetes Drug Shows Breakthrough Results in Phase II Trial, Achieves Key HbA1c Reductions - StockTitan
The Manufacturers Life Insurance Company Takes Position in Biomea Fusion, Inc. (NASDAQ:BMEA) - Defense World
Analysts Set Biomea Fusion, Inc. (NASDAQ:BMEA) Target Price at $39.36 - MarketBeat
Biomea Fusion, Inc. (NASDAQ:BMEA) Given Consensus Rating of “Buy” by Analysts - Defense World
Biomea Fusion (NASDAQ:BMEA) Receives Buy Rating from HC Wainwright - Defense World
Biomea Fusion to Host Conference Call to Announce Topline Results from Phase II COVALENT-111 Study in Patients with Type 2 Diabetes (T2D) - The Manila Times
Biomea Fusion to Host Conference Call to Announce Topline - GlobeNewswire
Biomea Fusion to Unveil Key Phase II Diabetes Trial Results: COVALENT-111 Data Release Set for December - StockTitan
Biomea Fusion (NASDAQ:BMEA) Receives "Buy" Rating from HC Wainwright - MarketBeat
Biomea Fusion's SWOT analysis: stock faces challenges amid clinical hold By Investing.com - Investing.com South Africa
Charles Schwab Investment Management Inc. Grows Position in Biomea Fusion, Inc. (NASDAQ:BMEA) - Defense World
Biomea Fusion's SWOT analysis: stock faces challenges amid clinical hold - Investing.com
Biomea Fusion Announces Oral and Poster Presentations of Icovamenib at the 22nd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC) - The Manila Times
Biomea Fusion Announces Oral and Poster Presentations of - GlobeNewswire
Biomea Fusion Unveils Breakthrough Preclinical Data: Menin Inhibitor Boosts GLP-1 Therapy Effectiveness - StockTitan
HC Wainwright Reaffirms “Buy” Rating for Biomea Fusion (NASDAQ:BMEA) - Defense World
HC Wainwright Reaffirms "Buy" Rating for Biomea Fusion (NASDAQ:BMEA) - MarketBeat
D. Boral Capital Reiterates "Buy" Rating for Biomea Fusion (NASDAQ:BMEA) - MarketBeat
Biomea Fusion Announces Preliminary Data from Ongoing COVALENT-103 Study of Investigational Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia - The Manila Times
Finanzdaten der Biomea Fusion Inc-Aktie (BMEA)
Umsatz
Nettogewinn
Free Cashflow
ENV
5.49%
0.79%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):